Updated Version 3 – Merck/Moderna Cancer Vaccine Can Reduce Melanoma Death or Recurrence Risk by 42%, Stock Price Falls
路透社2026/10/22 21:26Additional details from the Moderna CEO interview are included in paragraphs 10-12, and analyst comments are added in paragraph 17.
Michael Erman/Julie Steenhuysen
Reuters, October 22 - Moderna MRNA.O and Merck MRK.N said on Thursday that, in a large clinical trial, their mRNA cancer vaccine combined with Merck’s widely used immunotherapy reduced the risk of death or recurrence from melanoma by 42%, potentially paving the way for a new era of personalized treatments.
Since the two companies announced the trial’s success in August (link) (at that time, actual data were not disclosed), Moderna’s stock price has soared nearly fourfold, closing up by Wednesday. After the trial results were leaked on an oncology website early Thursday, the stock closed down more than 17%. Merck’s share price closed down about 1.8%.
Data from this phase III study involving more than 1,100 patients also showed that the combination therapy reduced the risk of cancer spreading by 38%.
This is the first dataset to show that combining a vaccine based on mutations unique to each patient’s tumor with a drug that boosts the immune system’s ability to fight cancer can effectively curb disease progression. The vaccine, named intismeran autogene, was tested alongside Merck’s blockbuster immunotherapy drug Keytruda (one of the world’s best-selling medicines).
Some analysts said this data could raise investors’ concerns about whether this technology can be broadly applied to other cancers.
Keytruda works by releasing the natural “brakes” cancer cells use to evade immune system attacks, while the vaccine instructs patients’ cells to produce copies of specific mutations for the immune system to seek out and destroy.
Moderna CEO Stephane Bancel said these data mark a new chapter in cancer treatment.
“With the ability to generate new T cells targeting specific tumors...the clinical impact is profound, and as we saw in phase II, this effect is very durable,” Bancel said in an interview.
Bancel said the two companies are preparing to file for U.S. approval and expect the cancer vaccine to hit the market in 2027.
The intismeran and Keytruda combination therapy is currently being tested in a variety of other cancers, including kidney, bladder, and lung cancer.
Bancel stated that he believes the vaccine should enhance efficacy “in all areas where Keytruda works,” but how much improvement it provides remains to be seen. Keytruda is approved for 19 types of cancer.
The CEO also said intismeran could be used as a standalone therapy for early-stage cancers.
Results from the phase III melanoma study, based on the first two years of patient data after treatment, are scheduled to be presented Saturday at the European Society for Medical Oncology annual meeting in Madrid.
Among patients who received the vaccine in addition to Keytruda, 82.2% had no cancer recurrence two years later, compared to 70% of those who received only Keytruda.
“This result is statistically highly significant and certainly not a chance finding,” said Dr. Hussein Tawbi, melanoma specialist at the University of Texas MD Anderson Cancer Center and clinical trial investigator, commenting on the outcome.
Several Wall Street analysts said before the meeting that investors expected the combination therapy to reduce the recurrence risk by 40% or more.
“Across oncology, we see expectations for pricing of the multibillion-dollar (intismeran) pipeline gradually diminishing,” wrote RBC analyst Trung Huynh. “This data makes us less optimistic, as melanoma should have been the best-case scenario.”
The trial tested nine doses of the vaccine in combination with Keytruda, starting treatment 13 weeks after surgical removal of melanoma lesions. The study compared the combined therapy to patients receiving only Keytruda, which is the standard treatment for melanoma.
(To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters is not liable for any damage or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.
Goldman Sachs' head of trading believes the current US stock market is repeating the scenario of late 2018, with monetary tightening and equity market pressure. The Goldman Sachs Financial Conditions Index has tightened by about 8 points in two weeks, reaching the highest level in a year. The selloff has broadened from tech stocks to defensive sectors. Gold and equities are declining simultaneously, possibly indicating investors are selling assets to raise cash, making gold a key indicator for observing liquidity stress.

Goldman Sachs Trader “Revisits the 2018 Playbook”: Still Clearly Remembers “On December 24th, Clients Asked Why the Market Dropped So Much—And I Had No Idea”
Brian Garrett pointed out that the current adjustment in the US stock market is similar to the sharp decline in Q4 2018: the S&P 500 has already experienced 42% of the corresponding drop, and the VIX is approaching its peak just before Christmas. If history repeats itself, the bottom of this cycle may appear in January next year. However, the credit market and Federal Reserve policy have yet to provide clear signals of a bottom.
Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis
On November 20th, Eastern Time, on its second day of trading, Anthropic's intraday price dropped to a low of $83.05, just 5 cents above the offering price of $83, and finally closed at $88.91, a decline of 8.50%. On the same day, the company's mathematician Levant Alperg announced on his personal website that he and Claude had found a candidate proof for the Riemann hypothesis, which has puzzled the mathematics community for 167 years, and released about 17 million lines of Lean formalized code.

As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.
According to Rentrak data, the global box office of "Grand Theft Auto VI" has also surpassed that of "Avengers: Endgame," the highest-grossing film of all time, which has a global box office of approximately $2.94 billion.
